MRT 5500
Alternative Names: COVID-19 mRNA vaccine - Sanofi/Translate Bio; COVID-19 vaccine - Sanofi/Translate Bio; MRT-5500; SARS-CoV-2 mRNA vaccine - Sanofi/Translate Bio; SP 0254Latest Information Update: 29 Aug 2022
At a glance
- Originator Sanofi Pasteur; Translate Bio
- Class COVID-19 vaccines; RNA vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued COVID 2019 infections
Most Recent Events
- 27 Jun 2022 Sanofi Pasteur terminates the first-in-human phase I/II VAW00001 trial in COVID-2019 infections (Prevention) in USA (IM), as the sponsor's decision is not to pursue further development of the product given the wide availability of authorized/approved mRNA COVID-19 vaccines (NCT04798027)
- 28 Oct 2021 Discontinued - Phase-I/II for COVID-2019 infections (Prevention) in USA (IM)
- 28 Oct 2021 Discontinued - Preclinical for COVID-2019 infections (Prevention) in France (IM)